These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38553651)

  • 1. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
    Prado MB; Adiao KJB; Turalde CWR; Dasig DA
    Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
    Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
    Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in Guillain-Barré Syndrome following a second therapeutic cycle - A single-centre retrospective observational study.
    Faustino P; Coutinho M; Brum M; Medeiros L; Ladeira F
    J Neurol Sci; 2022 Oct; 441():120368. PubMed ID: 35932547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
    Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
    Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and prognosis of patients with Guillain-Barré and acute transverse myelitis overlap syndrome.
    Guo F; Zhang YB
    Clin Neurol Neurosurg; 2019 Jun; 181():127-132. PubMed ID: 31039494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of IV Immunoglobulin in Indian Children With Guillain-Barré Syndrome.
    Kalita J; Kumar M; Misra UK
    Pediatr Crit Care Med; 2019 Jul; 20(7):652-659. PubMed ID: 30985608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course.
    Kalita J; Misra UK; Chaudhary SK; Das M; Mishra A; Ranjan A; Kumar M
    Eur J Neurol; 2022 Oct; 29(10):3071-3080. PubMed ID: 35837807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and real-world outcomes of Guillain-Barré syndrome in the Philippines.
    I Espiritu A; Separa KJNJ; Milla FJC; Adiao KJB; Leochico CFD; Jamora RDG
    Neurol Res; 2021 Dec; 43(12):995-1004. PubMed ID: 34229572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
    Wang J; Zhang Y; Wang M; Ren Y; Tang M; Liu L; Zhou D
    Int Immunopharmacol; 2022 Nov; 112():109192. PubMed ID: 36155283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
    Verboon C; Harbo T; Cornblath DR; Hughes RAC; van Doorn PA; Lunn MP; Gorson KC; Barroso F; Kuwabara S; Galassi G; Lehmann HC; Kusunoki S; Reisin RC; Binda D; Cavaletti G; Jacobs BC; ;
    J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1080-1088. PubMed ID: 34103340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravenous immunoglobulin and plasmapheresis on nerve conduction parameters compared to the natural course of Guillain-Barré syndrome.
    Kalita J; Mahajan R; Kumar M
    J Clin Neurosci; 2024 Jul; 125():76-82. PubMed ID: 38759351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?
    Godoy DA; Rabinstein A
    Arq Neuropsiquiatr; 2015 Oct; 73(10):848-51. PubMed ID: 26465402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.
    Hou HQ; Miao J; Feng XD; Han M; Song XJ; Guo L
    BMC Neurol; 2014 Oct; 14():202. PubMed ID: 25315010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.
    Kuwabara S; Kusunoki S; Kuwahara M; Yamano Y; Nishida Y; Ishida H; Kasuya T; Kupperman E; Lin Q; Frick G; Misawa S
    J Peripher Nerv Syst; 2024 Sep; 29(3):339-349. PubMed ID: 38987228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.